Search

Your search keyword '"O’Reilly, Richard J."' showing total 38 results

Search Constraints

Start Over You searched for: Author "O’Reilly, Richard J." Remove constraint Author: "O’Reilly, Richard J." Topic t cells Remove constraint Topic: t cells
38 results on '"O’Reilly, Richard J."'

Search Results

1. Ocular Outcomes after Treatment of Cytomegalovirus Retinitis Using Adoptive Immunotherapy with Cytomegalovirus-Specific Cytotoxic T Lymphocytes

2. 89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia.

3. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

4. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.

5. Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

6. Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency.

7. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

8. Novel strategies for adoptive therapy following HLA disparate transplants.

9. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation

10. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.

11. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes.

12. Epstein-Barr virus sustains tumor killers.

13. Host T-Cells Contribute to Immune Reconstitution and Improved Outcome in Recipients of CD34 Selected T-Cell Depleted Allografts (TCD HCT) with Full Hematopoietic Cell but Persistent Mixed T-Cell Chimerism.

14. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell–depleted hematopoietic cell transplantation in pediatric and young adult patients.

15. Addressing the envelope for gene delivery.

16. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell—depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

17. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.

18. Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

19. T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

20. High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell–Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

21. Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

22. Ex Vivo T Cell–Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission

23. T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease

24. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias.

25. Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell–Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303

26. T Cell–Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic Malignancies

27. Early CD4+ T-Cell Reconstitution Is an Excellent Predictor for Survival and Non-Relapse Mortality in Pediatric and Young Adult Patients Who Develop Moderate to Severe Acute Graft-Versus-Host-Disease; A Dual Center Validation.

28. Early CD4+ T Cell Reconstruction As Predictor for Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients: A Validation Cohort Analyses.

29. Baseline Immune Status Predicts Response to Adoptive Therapy with CMV Cytotoxic T-Cells for Refractory CMV.

30. Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell.

31. Durable Remission Following "Off-the-Shelf" Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies.

32. Conditioning Prior to CAR T Cells Predicts Response and Survival in Pediatric/Young Adult Relapse/Refractory (R/R) B-ALL.

33. Efficacy of Donor and 'Third Party' (Tabelecleucel) EBV-Specific T Cells for Treatment of Central Nervous System (CNS) EBV-PTLD.

34. 202 - CMV Seropositivity and Viremia Drive T-Cell Reconstitution after CD34-Selected Allogeneic HCT.

36. T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1

37. Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc.

38. Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation.

Catalog

Books, media, physical & digital resources